Structure Therapeutics Inc. earns a Strong Buy rating following robust phase 2b data for oral GLP-1R agonist Aleniglipron in obesity. Aleniglipron achieved placebo-adjusted weight loss up to -15.3% at ...
SAN FRANCISCO, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for ...
Placebo-adjusted mean weight loss of 11.3% (27.3 lbs) with 120 mg dose in the 36-week Phase 2b ACCESS study with a 10.4% adverse event-related treatment discontinuation Placebo-adjusted mean weight ...
In 2016, SlideShare had over 70 million unique visitors per day, and it was listed by Alexa as one of the top 100 most visited websites in the world. At its peak, it was such a powerhouse that Obama ...
The central government has, using its majority in the Lok Sabha, pushed through a Bill to replace the Mahatma Gandhi Rural Employment Guarantee Act (MGNREGA). The proposed draft — an outright “adhikar ...
At a moment where many Navy shipbuilding programs are stalling, the Constellation-class guided missile frigate stands out as the most behind schedule, the most over budget, and the most emblematic of ...
Thomas J. Brock is a CFA and CPA with more than 20 years of experience in various areas including investing, insurance portfolio management, finance and accounting, personal investment and financial ...
TIOBE Index for December 2025: Top 10 Most Popular Programming Languages Your email has been sent December’s TIOBE Index lands with a quieter top tier but a livelier shuffle just beneath it. The main ...
Will Kenton is an expert on the economy and investing laws and regulations. He previously held senior editorial roles at Investopedia and Kapitall Wire and holds a MA in Economics from The New School ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback